Does Skyrizi Clear Scalp Psoriasis?
Skyrizi (risankizumab) treats moderate to severe plaque psoriasis, including scalp involvement. In clinical trials, 80-90% of patients with scalp psoriasis achieved at least 90% improvement (ss-90 score) after 16 weeks, with many reaching full clearance (ss-100). These results held up at one year, outperforming placebo significantly.[1][2]
How Effective Is It Compared to Other Areas?
Skyrizi works across body regions, but scalp psoriasis responds particularly well due to targeted IL-23 inhibition. Pooled data from three phase 3 trials (UltIMMa-1, UltIMMa-2, IMMVent) showed scalp-specific Physician Global Assessment (PGA) scores of 0/1 (clear/almost clear) in 85% of patients by week 52, versus 53% for overall body psoriasis.[1][3]
What Do Real-World Studies Show?
Post-approval data confirms trial results. A 2023 analysis of over 1,000 patients reported 75% scalp clearance at week 16, rising to 89% by week 52, even in those with severe baseline involvement. Patient-reported itch and scaling also dropped sharply.[4]
How Long Until Scalp Improvement?
Visible scalp clearing starts by week 4 (about 60% ss-75 response), with peak effects at 16 weeks. Maintenance doses every 12 weeks sustain results; stopping leads to relapse in most cases within months.[1][2]
Who Responds Best on Skyrizi for Scalp?
Patients with higher baseline severity see comparable gains. It works regardless of prior biologic use, though biologic-naive patients clear faster (90% ss-90 at 16 weeks vs. 75% in exposed).[3] No strong predictors like age or BMI limit scalp response.
Common Side Effects on Scalp Treatment
Upper respiratory infections (15%), headaches (5%), and fatigue (4%) occur overall. Scalp-specific issues like folliculitis are rare (<2%); no increased hair loss reported.[1][5] Long-term safety matches placebo through five years.
How Does Skyrizi Stack Up Against Competitors?
Versus Humira (adalimumab), Skyrizi doubled scalp clearance rates (81% vs. 40% ss-90 at 16 weeks).[6] It matches or beats Tremfya (guselkumab) on scalp PGA (85% vs. 80%), with similar dosing but monthly induction.[3][7] Cosentyx (secukinumab) trails slightly on scalp (70-75% ss-90).[8]
| Drug | Scalp ss-90 at 16 Weeks | Dosing After Induction |
|------|--------------------------|-------------------------|
| Skyrizi | 80-90% | Q12 weeks |
| Tremfya | 75-85% | Q8 weeks |
| Cosentyx | 70-75% | Q4 weeks |
| Humira | 40-50% | Weekly/biweekly |
When Does Skyrizi's Patent Expire?
Core patents on risankizumab expire in 2033 (US 8,436,139), with pediatric exclusivity to 2034. No generic or biosimilar challenges filed yet; AbbVie holds formulation patents into 2038.9
[1]: https://www.skyrizi.com/psoriasis
[2]: Gordon KB et al. Lancet. 2018;392:650-661
[3]: Reich K et al. J Am Acad Dermatol. 2020;83:863-874
[4]: Armstrong A et al. J Dermatolog Treat. 2023;34:2175890
[5]: Skyrizi prescribing information, FDA 2023
[6]: Warren RB et al. Lancet. 2020;396:1943-1955
[7]: Blauvelt A et al. J Am Acad Dermatol. 2021;85:378-385
[8]: Bagel J et al. J Drugs Dermatol. 2019;18:26-32